Executives
-
Altshuler DavidEVP, Chief Scientific Officer -
Kewalramani ReshmaCEO & President
-
Biller JonathanEVP and Chief Legal Officer
-
Leiden Jeffrey MExecutive Chairman
-
Bozic CarmenEVP and CMO
-
Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
-
Sachdev AmitEVP Chief Patient & Ext Af Off
-
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
-
Ambrose KristenSVP & Chief Accounting Officer
?
Sachdev Amit
EVP Chief Patient & Ext Af Off
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1406338
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
55,325
Price per Share :
$418.27
Equivalence :
$23,140,787.75
Transaction History
-
S55,325 Shares After TransactionValue : $23,841,202.25Sold $13,789.76Transaction Date : 05/15/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
-
S60,798 Shares After TransactionValue : $25,642,772.46Sold $1,345,868.07Transaction Date : 02/21/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
-
F77,586 Shares After TransactionValue : $32,798,705.64$854,780.28Transaction Date : 02/09/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
-
S74,364 Shares After TransactionValue : $31,250,727.36Sold $1,354,013.28Transaction Date : 02/12/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.
-
A72,494 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.#3 Restricted stock unit award that vests in installments beginning on 02/17/2025.